Sign In
Buy ARCT
$7.60
-0.0500 (-0.654%)
At Close: Jun 03, 2026
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
04:01pm, Tuesday, 26'th May 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
12:31am, Friday, 08'th May 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
06:55pm, Thursday, 07'th May 2026
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
04:01pm, Thursday, 07'th May 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
04:01pm, Monday, 27'th Apr 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
04:06am, Friday, 17'th Apr 2026
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:52am, Wednesday, 25'th Mar 2026
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way f
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
02:39am, Wednesday, 25'th Mar 2026
Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 va
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
07:07am, Monday, 23'rd Mar 2026
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's hi
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
02:07am, Monday, 23'rd Mar 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat.c
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
02:02am, Thursday, 12'th Mar 2026
Arcturus Therapeutics (NASDAQ: ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cysti
Arcturus Therapeutics to Attend Upcoming Investor Conference
09:00am, Thursday, 05'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
11:14pm, Tuesday, 03'rd Mar 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 03'rd Mar 2026
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.11 per share a year ago.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
04:01pm, Tuesday, 03'rd Mar 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
